Search 

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org

We develop and apply fragment and structure -based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti -infectives and inflammation.
Our established group of experienced scientists is based at our fully -equipped research laboratories in Cambridge, UK. We integrate fragment -based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.
We have the experience and capabilities for progressing projects from target identification through to clinical candidate. We have generated lead compounds on enzymes, protein -protein interactions and GPCRs, leading to an average of one pre -clinical candidate per year, with disclosed programs for inhibitors of Chk1, Hsp90, Bcl -2, Mcl -1, FAAH and A2A.Previous and on -going collaborations include Novartis, Genentech, Servier, Lundbeck and Daiichi Sankyo.